Skip to main content

Table 3 The predictors of overall survival and native liver survival time in hepatoblastoma children receiving SIOPEL chemotherapy

From: Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma

Native liver survival Univariate analysis* Multivariate analysis
  Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
 AFP levels <1200 ng/mL (n = 21) vs. 1200 ng/mL (n = 10) after SIOPEL neo-adjuvant chemotherapy 6.01 1.49–24.28 0.01 4.54 1.05–19.64 0.04
 Female (n = 12) vs. male (n = 19) 0.36 0.10–1.39 0.14 - - -
 Age at diagnosis <=1.25 year-old (n = 16) vs. > 1.25 year-old (n = 15) 10.06 1.26–80.54 0.03 - - -
 No tumor recurrence (n = 23) vs. Tumor recurrence (n = 8) after tumor resection 7.23 1.80–29.06 0.005 5.55 1.32–23.29 0.02
Overall survival Univariate Analysis Multivariate Analysis
  Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
 AFP levels <1200 ng/mL (n = 21) vs. 1200 ng/mL (n = 10) after SIOPEL neo-adjuvant chemotherapy 6.59 1.27–34.11 0.02 - - -
 Female (n = 12) vs. male (n = 19) 0.18 0.03–0.97 0.04 - - -
 Age at diagnosis <=1.25 year-old (n = 16) vs. > 1.25 year-old (n = 15) 7.00 0.84–58.19 0.07 - - -
 No tumor recurrence (n = 23) vs. Tumor recurrence (n = 8) after tumor resection 4.22 0.94–18.94 0.06 - - -
  1. *Bonferroni correction was applied to adjust the P value in multiple comparison in univariate analysis of this analysis. The P value was adjusted to <0.0125 as statistical significant and 0.0125–0.025 as borderline significance in univariate analysis, and only variable with significant P value were forwarded to the multivariate analysis